Compounds and methods for degrading gspt1

A compound of Formula (I):

• wherein
• RE is selected from a group consisting of
• Xa is H or F;
• Ring A is a monocyclic or bicyclic ring (e.g., fused, spiro, bridged) selected from 4-12 membered saturated, partially unsaturated heterocyclic ring, or heteroaryl ring having 0-4 heteroatoms, in addition to the nitrogen already depicted in Ring A, independently selected from nitrogen, oxygen, and sulfur, wherein 0-4 methylene moieties (—CH2—) contained in the Ring A may be independently replaced with oxo (—C═O), —NH—, —N—C1-3 alkyl-, or —O—;
• RA0 is independently hydrogen, deuterium, halogen, C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, nitro, oxo, cyano, ORa, SRa, alkyl-Ra, NH(CH2)1-10Ra, C(O)Ra, S(O)Ra, SO2Ra, C(O)ORa, OC(O)Ra, NRbRc, C(O)N(Rb)Rc, N(Rb)C(O)Rc, —P(O)RbRc, -alkyl-P(O)RbRc, -alkyl-O—P(O)(Ra)(Rb), -alkyl-OC(O)N(Ra)(Rb), -alkyl-N(Ra)C(O)Rb, —S(O)(═N(Rb))Rc, —N═S(O)RbRc, ═NRb, SO2N(Rb)Rc, N(Rb)SO2Rc, or a monocyclic or bicyclic ring (e.g., fused, spiro, bridged) optionally substituted with one or more Rd;
• wherein the monocyclic or bicyclic ring is selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-11 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a benzene (i.e., phenyl) ring, a 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur,
• two of RA0 groups on the same atom or adjacent atoms, taken together with their intervening atoms to which they are attached, may optionally form a spiro or fused cycloalkyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl, each optionally substituted with one or more Rd;
• each of Ra, Rb, Rc, and Rd independently, is hydrogen, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, amine, nitro, oxo, cyano, hydroxy, ═O, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, C1-C6 aminoalkyl, —OR, —SR, —N(R)2, —Si(R)3, —S(O)2R, —S(O)2N(R)2, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)2, —C(O)N(R)OR, —C(R)2N(R)C(O)R, —C(R)2N(R)C(O)N(R)2, —OC(O)R, —OC(O)N(R)2, —OP(O)R2, —OP(O)(OR)2, —OP(O)(OR)(NR2), —OP(O)(NR2)2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)N(R)2, —N(R)S(O)2R, —NP(O)R2, —N(R)P(O)(OR)2, —N(R)P(O)(OR)(NR2), —N(R)P(O)(NR2)2, or —N(R)S(O)2R;
• wherein each R is independently hydrogen or C1-C6 alkyl;
• a subscript p0 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
• each stereocenter in the compound of Formula above is independently the R-enantiomer, the S-enantiomer or a mixture of R- and S-enantiomers;
• and
• each double bond in the compound of Formula above is independently cis or trans,
• or a pharmaceutically acceptable salt, enantiomer, stereoisomer or prodrug thereof.